Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Next Previous
Trial Profile

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors AbbVie

Most Recent Events

  • 15 Jun 2023 Results of an analysis assessing matching-adjusted indirect comparison (MAIC) of Pirtobrutinib vs Venetoclax continuous monotherapy from two clinical trials: NCT03740529 and NCT02141282 presented at the 28th Congress of the European Haematology Association
  • 29 Dec 2021 Status changed from active, no longer recruiting to completed.
  • 08 Dec 2020 Results (n=1138) of a retrospective analysis assessing rates of tumor lysis syndrome and outcomes and data were pooled from eight clinical studies: M15-550, M15-889, CLL14, M16-778, M14-032, M13-982, M14-728 and MURANO presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top